Jaypee Brothers
In Current Chapter
In All Chapters
X
Clear
X
GO
Normal
Sepia
Dark
Default Style
Font Style 1
Font Style 2
Font Style 3
Less
Normal
More
Rheumatic Diseases in Women & Children: Current Perspectives
Shefali K Sharma, Sujata Sawhney
SECTION 1: WOMEN ISSUES IN RHEUMATIC DISEASES
CHAPTER 1:
Rheumatoid Arthritis and Pregnancy
INTRODUCTION
FERTILITY IN RHEUMATOID ARTHRITIS
EFFECTS OF PREGNANCY ON RHEUMATOID ARTHRITIS
Pregnancy and RA Disease Activity
Postpartum Period and RA Disease Activity
Breastfeeding and RA Disease Activity
POSSIBLE MECHANISMS OF EFFECTS ON DISEASE ACTIVITY
During Pregnancy
Postpartum Period
PREGNANCY OUTCOMES IN RHEUMATOID ARTHRITIS
Ways to Improve Pregnancy Outcomes in Rheumatoid Arthritis
CONCLUSION
CHAPTER 2:
Pregnancy and SLE
IMMUNOLOGIC CHANGES IN PREGNANCY
EFFECT OF PREGNANCY ON SLE
EFFECT OF SLE ON PREGNANCY
MANAGEMENT OF SLE AND PREGNANCY
Preconception Assessment and Contraception
Antenatal Management
Pharmacotherapy During Pregnancy
MANAGEMENT OF PREGNANCY WITH ANTI-RO/LA POSITIVITY
MANAGEMENT OF PREGNANCY WITH APS
Breastfeeding
LONG-TERM CONSEQUENCES OF LUPUS PREGNANCY
CONCLUSION
CHAPTER 3:
Lupus Nephritis and Pregnancy
IS PREGNANCY POSSIBLE IN PATIENTS WITH LUPUS NEPHRITIS?
WHAT IS THE MOST PREFERRED TIME FOR PREGNANCY?
WHAT IF PATIENT WITH LN DECIDES TO GET PREGNANT?
Preconception Counseling
Antepartum Management
Management of Lupus Flare in Pregnancy
Postpartum Management
LONG-TERM OUTCOME OF PREGNANT LN PATIENTS
CONCLUSION
CHAPTER 4:
Pregnancy in Systemic Sclerosis
FERTILITY IN SYSTEMIC SCLEROSIS
PREGNANCY OUTCOMES
PREMATURITY
EFFECTS OF PREGNANCY ON SYSTEMIC SCLEROSIS
MANAGEMENT OF PREGNANCY
MANAGEMENT OF DELIVERY
SUMMARY
CHAPTER 5:
Antiphospholipid Syndrome in Pregnancy
INTRODUCTION
PATHOGENESIS OF ANTIPHOSPHOLIPID SYNDROME
DIAGNOSIS OF APS AND CRITERIA OF CLASSIFICATION
Clinical Features
General
Obstetric and Fetal Complications
LABORATORY FINDINGS IN APS
General
Anticardiolipin Antibody
Lupus Anticoagulant
β2GP1 Antibody Test
TREATMENT OF ANTIPHOSPHOLIPID SYNDROME IN PREGNANCY
CONCLUSION
CHAPTER 6:
Systemic Vasculitis and Pregnancy
INTRODUCTION
FERTILITY
CONCEPTION
PREGNANCY
POSTPARTUM PERIOD
PHARMACOTHERAPY RELEVANT TO PREGNANCY AND LACTATION
CONCLUSION
CHAPTER 7:
Antirheumatic Drugs in Pregnancy
MINIMAL MATERNAL AND FETAL RISK
Sulfasalazine (SSZ)
Hydroxychloroquine (HCQ)
SELECTIVE USE ALLOWED DURING PREGNANCY
Azathioprine (AZA)
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Corticosteroids (CS)
Tumor Necrosis Factor Alpha Inhibitors (TNF α)
MODERATE TO HIGH RISK OF FETAL HARM
Methotrexate (MTX)
Leflunomide (Lef)
Mycophenolate Mofetil (MMF)
Cyclophosphamide (CYC)
UNKNOWN RISK
Rituximab
Abatacept
Tocilizumab
SUMMARY AND RECOMMENDATIONS
CHAPTER 8:
Use of Antirheumatic Drugs During Lactation
INTRODUCTION
DRUGS SAFE TO BE USED DURING LACTATION
NSAIDs
Corticosteroids
Hydroxychloroquine
Sulfasalazine
POTENTIALLY SAFE DRUGS THAT CAN BE USED DURING LACTATION
Azathioprine
Cyclosporine A
Tumour Necrosis factor (TNF) Inhibitors
DRUGS TO BE AVOIDED DURING LACTATION
Methotrexate
Cyclophosphamide
SUMMARY AND CONCLUSIONS
CHAPTER 9:
Risk of Children Born to Mothers with Rheumatic Diseases
INTRODUCTION
RHEUMATOID ARTHRITIS
Genetic Susceptibility of RA
ANKYLOSING SPONDYLITIS
Genetic Susceptibility of AS
SYSTEMIC LUPUS ERYTHEMATOSUS
SYSTEMIC SCLEROSIS
FETAL OUTCOME AND RHEUMATIC DISEASES
Fetal Outcome
ANTI-RO (SSA) AND ANTI-LA (SSB) ANTIBODIES–THE NEONATAL LUPUS SYNDROME
COMMONLY USED IMMUNOSUPPRESIVE MEDICATIONS IN RHEUMATOLOGY AND RISKS THEREOF TO THE FETUS
SECTION 2: PEDIATRIC RHEUMATOLOGY
CHAPTER 10:
Juvenile Idiopathic Arthritis
CLINICAL VIGNETTE
INTRODUCTION
CLASSIFICATION
CLINICAL FEATURES
Oligoarticular JIA
Uveitis
Polyarticular JIA
Systemic-onset JIA (SoJIA)
Macrophage Activation Syndrome
Juvenile psoriatic arthritis (JPsA)
Enthesitis Related Arthritis (ERA)
ETIOLOGY AND PATHOGENESIS
Differential Diagnosis and Laboratory Abnormalities
Treatment
KEY POINTS
CONCLUSION
CHAPTER 11:
PUO and the Pediatric Rheumatologist
CASE VIGNETTE
INTRODUCTION
EPIDEMIOLOGICAL DATA FROM INDIA AND ABROAD
CLINICAL APPROACH
FUO
Fever Pattern
Constitutional Features
Our Patient
Multisystem Involvement
Our Patient
Arthritis
Rashes
Lymphadenopathy
Hypertension
Unwell Febrile Child with Features of Macrophage Activation
Investigative Approach
Our Patient
CEFUO7,14
Investigative Approach
In Conclusion
CHAPTER 12:
CTDs in Pediatrics
INTRODUCTION
TERMINOLOGIES
CLINICAL SUSPICION OF A CTD
DIFFERENTIAL DIAGNOSES
DIAGNOSTIC APPROACH
SLE
JUVENILE DERMATOMYOSITIS
SCLERODERMA
SJÖGREN'S SYNDROME
MCTD
UCTD
OVERLAP SYNDROME
CONCLUSION
CHAPTER 13:
Neonatal Lupus Syndrome
INTRODUCTION
EPIDEMIOLOGY
PATHOGENESIS
CLINICAL PRESENTATION
Cutaneous NL
Hepatic Disease
Hematological Involvement
Neurological Involvement
Cardiac Manifestations
Laboratory Investigations
For the Neonate
For the Mother
MANAGEMENT
Management of Pregnancy in Mothers with SLE or Sjogren's Syndrome
Recurrence Prevention
Prenatal Considerations
Treating Established CHB
Role of Steroids
Care of Neonates at Risk for Complete Heart Block
A POTENTIAL PROPHYLACTIC APPROACH
Transient Manifestations of NLS: Skin, Liver and Blood
PROGNOSIS
Neonatal Prognosis
Maternal Prognosis
Long-term Outcome
CONCLUSIONS/KEY MESSAGES
CHAPTER 14:
Childhood Vasculitis
INTRODUCTION
THE CASE
EPIDEMIOLOGY
CLASSIFICATION
PATHOGENESIS
CLINICAL FEATURES
Management of Vasculitis in Children—Diagnosis/Differential Diagnoses and Treatment
CLINICAL
LABORATORY
SEROLOGY
RADIOLOGY
Digital Subtraction Angiography (DSA)
MR angiogram (MRA)
COMPUTERISED TOMOGRAPHY AND ULTRASONOGRAPHY
2-D ECHOCARDIOGRAM
HISTOLOGY
Skin
DIFFERENTIAL DIAGNOSES OF PRIMARY VASCULITIDES
TREATMENT STRATEGIES
PROGNOSIS
CHAPTER 15:
Transition of the Child with a Rheumatic Disease to the Adult Team
INTRODUCTION
DEFINING TRANSITION
WHAT ARE THE DIFFERENCES BETWEEN TRANSITION AND TRANSFER?
WHAT ARE THE STEPS TO SUCCESSFUL TRANSITION?
WHY IS TRANSITION IMPORTANT FOR YOUTH WITH RHEUMATIC DISEASES?
WHAT ARE THE DETERMINANTS OF SUCCESSFUL TRANSITION AND TRANSFER?
WHAT ARE THE MODELS OF TRANSITION?
WHAT GOALS SHOULD BE ADOPTED FOR A PEDIATRIC RHEUMATOLOGY TRANSITION PROGRAM?
WHAT ARE THE FACTORS DETERMINING A PATIENT'S READINESS TO TRANSFER CARE TO AN ADULT RHEUMATOLOGIST?
WHAT IS THE CURRENT SCENARIO IN INDIA?
EXAMPLES OF WEB-BASED RESOURCES FOR TRANSITION
United Kingdom
Australia
USA and Canada
SUMMARY
INDEX
TOC
Index
×
Chapter Notes
Save
Clear